Jump to the top of the page

Investment Banking

The Quarterly Rx: Q3 2022 U.S. Biopharma Recap

While biopharma markets stabilized in Q3 2022—providing issuers with the most constructive financing environment we have seen year-to-date—macroeconomic issues remain the key headline risk for the near term. Key biopharma indices bounced off multiyear lows, driven by encouraging signs of M&A, meaningful positive clinical news, and broad sector short covering. William Blair's Biopharma team shares perspectives in “The Quarterly Rx: Q3 2022 U.S. Biopharma Recap.

Complete the form below to download your copy of the report.

Delivered to Your Inbox

Stay up-to-date with the latest William Blair news and insights

Subscribe to News Alerts

More News and Insights

  • Economics Weekly: Where Have All the Foreign Profits Gone

    In this Economics Weekly, Richard de Chazal examines what has changed, why the foreign share of U.S. corporate profits has collapsed, and what that means for investors.

    Read more

  • William Blair Investment Management Launches First ETFs, Expanding International and Emerging Markets Expertise to Active ETF Market

    New ETFs extend firm’s more than three-decade heritage in non-U.S. investing to a transparent, tax-efficient structure.

    Read more

  • Marex Group Limited: Initiation of Research Coverage

    William Blair initiated research coverage of Marex Group Limited (MRX $71.95), a high-growth diversified specialty brokerage firm focused on global commodity and financial markets.

    Read more
See more insights

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures